44 results about "Adverse drug reaction" patented technology

Described is a method of managing adverse reactions that may occur during a medical procedure that involves the administration of contrast media. The method includes acquiring, by a data acquisition unit, information about a patient and an upcoming medical procedure that involves the administration of contrast media, computing in advance of the medical procedure, by a risk assessment unit, a prediction of a risk that the patient will experience an adverse reaction to the contrast media based on the information about the patient and the upcoming medical procedure, and presenting to one or more medical personnel in advance of the medical procedure, by a risk alert unit, an indication of the risk in a visually perceptible form. Also described are systems and software that implement methods of managing adverse reactions.

The present invention provides a combination preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The combination preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin. The combination preparation of the present invention is also advantageous in that it exhibits an outstanding effect in inhibiting blood platelet aggregation despite a reduction in the amount of aspirin ingested, and in that it converts clopidogrel resistance into susceptibility and prevents serious adverse reactions caused by clopidogrel resistance and in that it can be stored over the longer term since it is stable under common storage conditions.

The invention discloses a genetic testing method for risk of causing serious adverse reactions of carbamazepine. The genetic testing method comprises the following steps: collecting oral mucosa cells of a subject, extracting genome DNA (deoxyribonucleic acid) of the oral mucosa cells, testing HLA (human leukocyte antigen)-B*1502 allelotype of the genome DNA and evaluating the risk of causing the serious adverse reactions of the skin of an anti-epileptic medicament-carbamazepine, thereby providing reference basis for clinical individual medication.

Provided is an oxyntomodulin analogue. The analogue comprises GCGR and GLP-1R dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions. The analogue can be used to prepare medication for treating hyperphagia, obesity and diabetes.

A method and apparatus for providing the information of adverse drug effects. The method includes: extracting at least a first information and a second information in basic information of a drug from a drug information source; matching the drug with a particular drug-related concept in a structured and normalized terminology system according to the first and the second information; extracting, from the drug information source, the information of Adverse Drug Effects associated with the drug; and matching the information of Adverse Drug Effects with a particular disorder-related concept in the structured and normalized terminology system; wherein the matching is along different paths in at least two disorder-related classified hierarchies. The invention can extract, standardize, and normalize information relating to adverse drug effects to help the integration, search, calculation, and propagation thereof.

The invention relates to a glossy ganoderma and grass jelly soft extract and a preparation method thereof. Glossy ganoderma is used as a main raw material, and through cooperation of an appropriate quantity of Chinese mesona herbs, extractability raw materials are added or not added, fruit and vegetable juice is added or not added, nutrients are added or not added, during extract collection, an appropriate extract collecting agent is selected for cooperation of extract collection, an optimal recipe combination can be obtained, namely the glossy ganoderma and grass jelly soft extract being balanced, comprehensive and reasonable in nutrient components, orderly and appropriate in collocation of main materials and auxiliary materials, unique in flavor, and fine and smooth in mouth feel can beobtained. The food does not have requirements for eating crowds and eating amount limiting, the glossy ganoderma and grass jelly soft extract can be suitable for broad consumption groups, is free fromadverse drug reactions after being eaten, and does not have efficacy requirements of health-care foods. The eating scope of conventional glossy ganoderma products is enlarged, new vitality is provided for food markets, and higher economic value is created for society.

The invention discloses a layering strategy-based adverse drug reaction data shadowing effect eliminating method. According to the method, a data shadowing effect eliminating method is researched in adverse drug reaction signal detection on the basis of the adverse drug reaction report data of China, so that a layering strategy-based adverse drug reaction data shadowing effect eliminating model isdesigned; the data are layered on the whole according to the frequencies of the presence of drugs, adverse reactions and drug-adverse reaction pairs in the report data; and data detection is performed on the layered data through adopting an IC method. According to the invention, reports in which the frequencies of the presence of the drugs, adverse reactions and drug-adverse reaction pairs belongto the same order of magnitude are grouped into the same layer, so that the problem of data shadowing effects caused by excessively large difference of the frequencies of the presence of the drugs, adverse reactions and drug-adverse reaction pairs can be solved, and therefore, the data shadowing effects can be eliminated. With the method of the invention adopted, suspicious signals in the adversedrug reaction reports can be the accurately and reliably detected. The method has important reference significance in clinical care and drug supervision links.

The present invention provides a pharmaceutical composition for treating cancer, the composition comprising as the active ingredient a compound represented by general formula I: C-[-CH2-O-(-CH2CH2-O-)­n-X1-CHR1-O-CO-NR2-CH2-X2]4 (I) (where X1-CHR1-O-CO-NR2 is a linker, X1 is a spacer, R1 is an optionally substituted C1-4 alkyl, R2 is a phenyl or substituted phenyl group, X2 is SN-38, and n is an integer of 200 to 1,000). The composition is characterized by the following: that the composition can be used in a subject having cancer at a dosage regimen that calls for parenteral administration of a single dose of approximately 0.01 to 11 µmol/kg body weight at a frequency of once a week every other week for at least two administrations; and that the composition does not have irinotecan-like adverse reactions but does impart the same or better cancer proliferation-inhibiting activity as irinotecan at a dose that is 1/10 (molar ratio) or less that of irinotecan. Also provided is a method for treating cancer.

The invention belongs to the technical field of medicines, and particularly relates to a compound multi-component injection and a preparation process and application thereof. The compound multi-component injection is used for treating sepsis, cannot cause adverse reactions such as allergy and is good in stability.

The invention relates to a direct dispensing type double-pipe infusion soft bag which comprises an integrally formed bag body, an infusion pipe port and a medicine filling port. The outer end of the medicine filling port is connected with a dispensing device in a sealed mode, the connection portion of the medicine filling port and the dispensing device is provided with a rubber plug, the dispensing device is a cylindrical container with an opening in the lower end, the dispensing device comprises a puncture device, the two ends of the puncture device are provided with sharp ends, the wall of the dispensing device is provided with an annular protrusion, the annular protrusion limits downward sliding of the puncture device, and the middle lower portion of the lower sharp end is provided with a protrusion. By means of the soft bag, puncture times during dispensing are reduced, stability of the puncture device in the sliding process is guaranteed, sealing performance of the overall structure is improved, entering of pollutant bacteria is avoided, the probability that puncture fragments enter infused medicine is lowered, the risk that medical accidents are caused due to adverse reactions of medicine in infusion is reduced, the structure is simple, secondary assembling is not needed, the medicine filling port and the infusion pipe port are both downward, and falling of a penicillin bottle is avoided.

The invention provides a method of evaluating tendency of adverse reactions of a drug. The method comprises the following steps of: excluding interference information according to structural characteristics of the drug and quantitative characteristics of an adverse reaction tendency value and establishing an evaluated quantitative relation model between the structural characteristics and the adverse reaction tendency value; and applying the model to evaluate safety of the drug, wherein the accuracy of evaluating the adverse reaction tendency value of the drug can be effectively increased and the consumption of scientific research resources is lowered. The method is targeted, can remarkably reduce the blindness of a common method of evaluating the adverse reaction tendency value, provides evaluated drug safety risk warn for safe monitoring in a research process of the drug and after the drug is marketed, and provides pre-warning to adverse reactions of the drug, so as to improve the foreseeability and the medical safety level of drug monitoring, and provide reference to personal medication.

The invention provides a drug risk assessment method based on an ADR monitoring report and an outlier detection technology, and the method comprises the following steps: obtaining an original ADR database, and carrying out the normalization processing of drug names and adverse reaction names in the original database; determining outlier detection research objects and parameters: calculating a PRRvalue and an IC value of each drug-adverse reaction combination by adopting a proportional imbalance method, and constructing a spatial vector model by taking the PRR value and the IC value as features; determining a clustering number by utilizing an elbow rule, and finding a parameter k for minimizing a cost function; clustering by adopting a K-Means clustering algorithm, and randomly selecting kdata points as an initial centroid for clustering iteration according to a clustering number k determined by an elbow rule; calculating outlier scores of all the data points; and determining a threshold value and carrying out outlier detection on each cluster: setting the threshold value according to outlier score conditions, and determining points exceeding the threshold value as outliers. The invention provides an abnormal signal detection method for drug alert.

The invention relates to the technical field of medical systems, in particular to a system and method for improving the adverse reaction report rate of clinical drugs. The system comprises a login module used for allowing a user to login the system, a report form filling module used for filling a report form after login, a report form viewing module used for viewing the filled report form, a database module used for storing related data including login information data and report table information data, a scoring module used for scoring the filled report form so as to enable a related user toobtain scores according to the scores and used for evaluating the filled report form and allowing the user to change the report form subsequently and obtain more points after the change, and a creditexchange module used for exchanging commodities or services by using the credits. The invention has the beneficial effects that by simplifying the process and awarding mechanism of the report form, the interest of the masses and all institutions in reporting the adverse reaction report form is stimulated, and the problem that the report missing rate of adverse reaction reports is high is solved.

The invention provides a patient medicine taking tracking management system, an electronic medicine box and a device. The system is composed of a cloud server, a pharmacist APP, a pharmacist PC clientside, a physician APP, a physician PC client side, a medicine manufacturer APP, a medicine manufacturer PC client side, a patient APP, the electronic medicine box and self-examination equipment. Thepharmacist APP, the pharmacist PC client side, the physician APP, the physician PC client side, the medicine manufacturer APP, the medicine manufacturer PC client side and the patient APP exchange data information through the cloud server to achieve a patient medicine taking tracking management function. A patient can take medicines timely and correctly in the whole process, and the medicine taking compliance of the patient is improved; a physician and a pharmacist can track the diseases condition and medicine taking condition of the patient and dynamically grasp medicine taking information and disease condition information of the patient in real time, tracking and guiding services are provided for the patient in the whole process, and the treatment effect on diseases is improved; a medicine manufacturer can monitor adverse reaction information of medicines and count dosage information of the medicines, and a reference is provided for guiding the production of the medicines.

The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for treating undesired physiological adverse reactions due to the administration of a therapeutic molecule containing the L-RNA. Alternatively, an endogenous target RNA may also be split by the L-ribozyme.

The invention discloses application of polymorphism of retinoid X receptor alpha (RXRA) genes to adverse reactions of antituberculous drugs, and relates to the field of screening of adverse reactionsof tuberculous drugs. The invention discloses application of the polymorphism of the RXRA genes to tuberculosis treatment, it is found that through detection of the polymorphism of the RXRA genes, therisk of generating the adverse reactions after tuberculous patients are treated by the antituberculous drugs can be predicted, certain support is provided for avoiding the adverse reactions caused bythe related antituberculous drugs, and certain guidance is also provided for drug use of the tuberculous patients.

The invention discloses a method and kit for detecting SNP locus genotypes having adverse reactions to CTX drugs. The invention relates to the fields of molecular biology and medicine; according to the kit provided by the invention, aiming at SNP loci with cyclophosphamide adverse reaction risks and in human genomic DNA, namely a GSTP1 gene rs1695, specific primers and probes are designed, a hybridization reaction with MagPlex-TAG magnetic beads with corresponding report genes is performed, and detection is performed on a luminex 200 instrument through chromogenic reaction; a base type of eachSNP locus is judged through reading and interpretation of signal values. The kit has the beneficial effects that the specific primers, probes and report gene probe sequences are designed by using theSNP loci related to the adverse reaction risks of cyclophosphamide used by patients with systemic lupus erythematosus and other diseases, and the types of the SNP loci can be detected in a typing manner. The detection kit provided by the invention can detect the types of the SNP sensitively and quickly, and can provide reliable experimental evidence for predicting medication adverse reaction risks of the patients with systemic lupus erythematosus, and the clinical treatment selection is guided.